Company intelligence / Profile preview

BioSymetrics

New York City, New York, United Statesbiosymetrics.com ↗

Ownership: Private
Employees: ~16
Development stage: Preclinical

Overview

BioSymetrics has developed an AI-powered phenomics platform to accelerate drug target identification and validation. Their lead program in epilepsy has identified small molecule hits that reverse seizure phenotypes in zebrafish models by targeting KCC2 hypofunction. The company plans to initiate multiple new therapeutic programs across cardiac, rare, and neurodegenerative disease areas but has not reported human clinical trial results yet.

Therapeutic areas: CardiovascularRare DiseasesNeurology
Modalities: Small molecules (noted in epilepsy/seizure program)AI-driven target discovery and phenomics-based approaches
Industry: Biotech

Drug pipeline

1 asset

BIOS-1073

Pre-clinical

Indications: Epilepsy

Partnerships

Janssen Pharmaceuticals [Johnson & Johnson subsidiary]Sema4 [now GeneDx]Northwell HealthMt. Sinai Health System

Beyond the preview

Go deeper on BioSymetrics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSymetrics.

Explore the full profile